Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Kristen Rodgers(Johns Hopkins University), Rosalyn A. Juergens(McMaster University), Julie R. Brahmer(Johns Hopkins University), Xiaoyu Pan(Peking University), Frank P. Vendetti(University of Pittsburgh), Hariharan Easwaran(Johns Hopkins University), Janis M. Taube(Bloomberg (United States)), Daniel J. Weisenberger(University of California, Los Angeles), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Suzanne L. Topalian(Bloomberg (United States)), Zhengzong Du(Johns Hopkins University), Cynthia A. Zahnow(Johns Hopkins University), Drew M. Pardoll(Bloomberg (United States)), Princy Parsana(Johns Hopkins University), Richard D. Carvajal(Northwell Health), Peter A. Jones(Van Andel Institute), Wim VanCriekinge(Ghent University), Timothy DeMeyer(Ghent University), Wei Wang(Johns Hopkins University), Peter W. Laird(University of Southern California), Malcolm V. Brock(Johns Hopkins University), Ray-Whay Chiu Yen(Johns Hopkins University), Salina Tsai(Lovelace Respiratory Research Institute), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Helai P. Mohammad(Arysta LifeScience (France)), Alexander Koch(Ghent University)
Cited by 391
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k